Attending Biotech and Pharma
Bioregion Partners
Why attend BOS 2007?
• Network with your peers from international biotech & pharma discovery/development.
• Exchange ideas and transfer knowledge with regards to successful outsourcing.
• Hear from leading authorities in key areas of discovery & development such as target validation, computational chemistry, medicinal chemistry & process R&D.
• Organise 1:1 meetings with leading discovery/development CROs & industry consultants.
Welcome to the Biotech Outsource Strategies series of forums organised and run by Bio2Business Ltd (www.bio2business.com). BOS is the evolution of an ongoing 3 year project by Bio2Business Ltd to facilitate R&D outsourcing and partnering for international biotech and pharmaceutical companies.
A Day of Partnering & Networking
BOS is primarily a partnering event; a forum to connect international biotech & pharma outsource executives with a network of specialist CROs. BOS2007 has a clear focus on small molecule drug discovery/development. As a delegate attending BOS in London you can expect to meet with a significant number of top quality niche global CROs at the discovery/development interface who offer high quality, reliable services. You will be able to organise 1 to 1 meetings with CROs, consultants and fellow development executives as you wish throughout the day using Bio2Business partnering software. Informal networking over coffee, lunch and closing drinks receptions will give you an ideal opportunity to make links with fellow discovery/development executives and exchange ideas and approaches to outsourcing.
Speaker Programme
In addition to providing a partnering forum for discovery & development attendees, BOS also strives to deliver an outstanding programme of speakers to deliver perspective and approaches in the field of drug discovery & development. This year we are pleased to announce a first class programme of speakers including; Professor Peter Jenner, CSO Proximagen Neurosciences ; Professor Graham Richards, Professor of Chemistry Oxford University; Dr Andy Merritt, Director of Discovery Medicinal Chemistry GlaxoSmithKline; Dr Dave Ennis, acting Director of Chemistry, AstraZeneca; Hooshang Zavareh, Managing Director of ChemPharmaServe Ltd and Dr Alan Davidson, Director of Pre-Clinical Development Chroma Therapeutics.
Our Speakers are international experts in their areas of specialisation including targeted validation, computational chemistry, medicinal chemistry and process R&D. Equally as important we are very pleased to wellcome the following chairs for our discovery, development and case study modules; Dr Chris Hill, Senior VP Research Organon Laboratories Ltd; Prof Hans Jurgen Federsel, Director of Science Global Process R&D AstraZeneca & Sue Jackson, Principal Consultant Wood Mackenzie Ltd.
We believe we have the right blend between academia, biotech, pharma and service industry to make for an excellent day of discussion, debate and knowledge transfer which will run in parallel to one to one meetings that you wish to organise.
Key Sponsors
Gold CRO Sponsors
Silver CRO Sponsor
Corporate Sponsor
University Sponsor
